Strides Pharma Gets Nod For Prednisone Tablets; Stock Sheds Over 1%
Strides Pharma Science's step-down subsidiary, Strides Pharma Global Pte., Singapore, has received approval from the US Food & Drug Administration for Prednisone tablets, Strides Pharma announced in a regulatory filing to the stock exchanges on Monday. At 2:37 pm, Strides Pharma shares were trading at Rs 698.10, lower by 1.72 per cent, on the BSE, after touching an intra-day high of Rs 714.40.
The pharma company has received approval for Prednisone Tablets USP, 2.5 mg and 5 mg. The product is bioequivalent and therapeutically equivalent to deltasone tablets, 2.5 mg and 5 mg of Pharmacia and Upjohn, Strides Pharma added.
Prednisone drugs, also known as corticosteroids, are used as anti-inflammatory and immunosuppressant medications for the treatment of allergic disorders, skin conditions, ulcerative colitis and arthritis. According to IQVIA MAT September 2020 data, the US market for Prednisone tablets is about $30 million. The product will be manufactured at the company's flagship facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.
Strides Pharma has 127 cumulative ANDA filings with USFDA, of which 93 ANDAs have been approved and 34 are pending approval.
The BSE Sensex was at 44,169.24, higher by 287 points and NSE Nifty was at 12,950.85, up 90 points at the time.
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
-
India Is Going Abroad For Critical Minerals. But It May Take Years To Pay Off | The Reason Why
Although India's steps are in the right direction, they remain modest compared with India's growing dependence.
-
When Everyone Has AI, What Gives You An Edge?
India's young workforce is entering an uncertain world of work where powerful AI tools are becoming widely accessible. The advantage will belong to those who combine deep expertise with digital fluency, and the distinctly human capabilities that technology cannot manufacture.
-
Wrong Labels, High Pesticide Residues Holding Back Agri Exports | The Reason Why
India needs stronger domestic food-safety and labelling standards, with best practices becoming part of everyday business for farmers, traders and food companies.
